Table 1 Dataset of mutations studied.

[42]

Mutagenesis experiments for APOBEC3G

L260A, C261A, W168A, C281A, C288A, C308A L234A, L235A, F241A, L253A, L371A

[44]

AA replacement improving solubility

N159D

[45]

AA Contribution to solubility

Y76 D, Y76R, Y76 S, Y76E, Y76K, Y76G, Y76A, Y76 H, Y76N, Y76P, Y76C, Y76 M, Y76V, Y76L, Y76I, Y76F, Y76W

[46]

mutagenesis of Ab42 s'Alzheimer's peptide

F19 D, F19E, F19N, F19R, F19Q, F19 H, F19T, F19G, F19K, F19P, F19 S, F19A, F19C, F19 M, F19W, F19Y, F19L, F19V, F19I

[47]

Polymerization and solubility of recombination

E6F, E6W, E6L

[48]

Genetic selection for protein solubility

(H6Q/V12A/V24A/I32M/V36G), (V12A/I32T/L34P), (V12E/V18E/M35T/I41N), (F19S/L34P), (L34P), (F4I/S8P/V24A/L34P), I32S

[49]

Isolation of viral coat protein mutants

(A26T/I118F), N27 S, A107T (N24S/C46R/A96V/N116S), Q109L, (V48A/Q109H), I104V, (N12D/S34G/S52P/I92M/C101R/Q109L/S120T), (A21S/N24D/Q40R/V79A), (Q6L/N12D/I33T/R56C/F95L), (T15N/N24S/V29A/W32C/T45S/I60T/N98Y/I104N/S126P), (V61E/L103F/K106R/Y129H), (F4S/W32R/Q50R)

[50]

Improved solubility of TEV protease

(T17S/N68D/I77V), (T17S/R80S)

[51]

Primary structure and solubility

W131A, V165K, A104T, Y203 H, W140F, C19Y, P28T, V32 M, G36R, T288 M, A384P, C70 S, C26 S, C93 S, W140K, W140L, W140C, (W86F/W140F), (W130F/W140F), P28K, H44Y, (W86F/W130F/W140F), R68C, G346 S, G349 S, A198V

[52]

Substitutions affecting protein solubility

K97R, (K113F/W140K), (K113F/W140L), (K113F/W140C), K63 M, L104 M, T90A, L87 M, (T90A/E97A), L127 M, V74F, E97A, K69 M, (T345L/M358R), M358L, K97G, K97V, W140C, L10N, L10 D, L10T

[53]

Dual selection for functionally active mutants

(Y35Q/F37R), (Y35L/F37T), (Y35G/F37L), (Y35L/F37R), K27E

[54]

Assay for increased protein solubility

K185F, K185I, K185V, K185L, K185N, K185D

[55]

Phage T4 vertex protein gp24

(E89A/E90A)

[56]

Human cell surface receptor CD58

(Q21V/S85T/S1F/K9V/K58V/G93L)

[57]

Solubility and folding of a genetic marker

W232E, Y242E, I317E, (G32D/I33P)